293 related articles for article (PubMed ID: 27378505)
1. Gallium, a promising candidate to disrupt the vicious cycle driving osteolytic metastases.
Strazic-Geljic I; Guberovic I; Didak B; Schmid-Antomarchi H; Schmid-Alliana A; Boukhechba F; Bouler JM; Scimeca JC; Verron E
Biochem Pharmacol; 2016 Sep; 116():11-21. PubMed ID: 27378505
[TBL] [Abstract][Full Text] [Related]
2. A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro.
Yoneda T; Williams PJ; Hiraga T; Niewolna M; Nishimura R
J Bone Miner Res; 2001 Aug; 16(8):1486-95. PubMed ID: 11499871
[TBL] [Abstract][Full Text] [Related]
3. MMP-13 stimulates osteoclast differentiation and activation in tumour breast bone metastases.
Pivetta E; Scapolan M; Pecolo M; Wassermann B; Abu-Rumeileh I; Balestreri L; Borsatti E; Tripodo C; Colombatti A; Spessotto P
Breast Cancer Res; 2011 Oct; 13(5):R105. PubMed ID: 22032644
[TBL] [Abstract][Full Text] [Related]
4. Preclinical evaluation of zoledronate using an in vitro mimetic cellular model for breast cancer metastatic bone disease.
Dedes PG; Kanakis I; Gialeli Ch; Theocharis AD; Tsegenidis T; Kletsas D; Tzanakakis GN; Karamanos NK
Biochim Biophys Acta; 2013 Jun; 1830(6):3625-34. PubMed ID: 23395844
[TBL] [Abstract][Full Text] [Related]
5. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway.
Bendre MS; Margulies AG; Walser B; Akel NS; Bhattacharrya S; Skinner RA; Swain F; Ramani V; Mohammad KS; Wessner LL; Martinez A; Guise TA; Chirgwin JM; Gaddy D; Suva LJ
Cancer Res; 2005 Dec; 65(23):11001-9. PubMed ID: 16322249
[TBL] [Abstract][Full Text] [Related]
6. Angiogenesis inhibitor TNP-470 inhibits human breast cancer osteolytic bone metastasis in nude mice through the reduction of bone resorption.
Sasaki A; Alcalde RE; Nishiyama A; Lim DD; Mese H; Akedo H; Matsumura T
Cancer Res; 1998 Feb; 58(3):462-7. PubMed ID: 9458090
[TBL] [Abstract][Full Text] [Related]
7. Gold clusters prevent breast cancer bone metastasis by suppressing tumor-induced osteoclastogenesis.
Zhang Z; Yao Y; Yuan Q; Lu C; Zhang X; Yuan J; Hou K; Zhang C; Du Z; Gao X; Chen X
Theranostics; 2020; 10(9):4042-4055. PubMed ID: 32226538
[No Abstract] [Full Text] [Related]
8. Parathyroid hormone-related protein and bone metastases.
Guise TA
Cancer; 1997 Oct; 80(8 Suppl):1572-80. PubMed ID: 9362424
[TBL] [Abstract][Full Text] [Related]
9. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases.
Hiraga T; Williams PJ; Mundy GR; Yoneda T
Cancer Res; 2001 Jun; 61(11):4418-24. PubMed ID: 11389070
[TBL] [Abstract][Full Text] [Related]
10. Gentian violet inhibits MDA-MB-231 human breast cancer cell proliferation, and reverses the stimulation of osteoclastogenesis and suppression of osteoblast activity induced by cancer cells.
Yamaguchi M; Vikulina T; Weitzmann MN
Oncol Rep; 2015 Oct; 34(4):2156-62. PubMed ID: 26260090
[TBL] [Abstract][Full Text] [Related]
11. Sagopilone inhibits breast cancer bone metastasis and bone destruction due to simultaneous inhibition of both tumor growth and bone resorption.
Strube A; Hoffmann J; Stepina E; Hauff P; Klar U; Käkönen SM
Clin Cancer Res; 2009 Jun; 15(11):3751-9. PubMed ID: 19470728
[TBL] [Abstract][Full Text] [Related]
12. Tetrahydrofurofuran-type lignans inhibit breast cancer-mediated bone destruction by blocking the vicious cycle between cancer cells, osteoblasts and osteoclasts.
Jun AY; Kim HJ; Park KK; Son KH; Lee DH; Woo MH; Chung WY
Invest New Drugs; 2014 Feb; 32(1):1-13. PubMed ID: 23673814
[TBL] [Abstract][Full Text] [Related]
13. Osteoclastic miR-214 targets TRAF3 to contribute to osteolytic bone metastasis of breast cancer.
Liu J; Li D; Dang L; Liang C; Guo B; Lu C; He X; Cheung HY; He B; Liu B; Li F; Lu J; Wang L; Shaikh AB; Jiang F; Lu C; Peng S; Zhang Z; Zhang BT; Pan X; Xiao L; Lu A; Zhang G
Sci Rep; 2017 Jan; 7():40487. PubMed ID: 28071724
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms of tumor-bone interactions in osteolytic metastases.
Chirgwin JM; Guise TA
Crit Rev Eukaryot Gene Expr; 2000; 10(2):159-78. PubMed ID: 11186331
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2.
Yoneda T; Sasaki A; Dunstan C; Williams PJ; Bauss F; De Clerck YA; Mundy GR
J Clin Invest; 1997 May; 99(10):2509-17. PubMed ID: 9153295
[TBL] [Abstract][Full Text] [Related]
16. RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model.
Canon J; Bryant R; Roudier M; Branstetter DG; Dougall WC
Breast Cancer Res Treat; 2012 Oct; 135(3):771-80. PubMed ID: 22926264
[TBL] [Abstract][Full Text] [Related]
17. CSF-1 blockade impairs breast cancer osteoclastogenic potential in co-culture systems.
Liverani C; Mercatali L; Spadazzi C; La Manna F; De Vita A; Riva N; Calpona S; Ricci M; Bongiovanni A; Gunelli E; Zanoni M; Fabbri F; Zoli W; Amadori D; Ibrahim T
Bone; 2014 Sep; 66():214-22. PubMed ID: 24956020
[TBL] [Abstract][Full Text] [Related]
18. Transforming growth factor-beta1 is the predominant isoform required for breast cancer cell outgrowth in bone.
Mourskaia AA; Dong Z; Ng S; Banville M; Zwaagstra JC; O'Connor-McCourt MD; Siegel PM
Oncogene; 2009 Feb; 28(7):1005-15. PubMed ID: 19079339
[TBL] [Abstract][Full Text] [Related]
19. Inhibition by interleukin 18 of osteolytic bone metastasis by human breast cancer cells.
Nakata A; Tsujimura T; Sugihara A; Okamura H; Iwasaki T; Shinkai K; Iwata N; Kakishita E; Akedo H; Terada N
Anticancer Res; 1999; 19(5B):4131-8. PubMed ID: 10628364
[TBL] [Abstract][Full Text] [Related]
20. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line.
Price JT; Quinn JM; Sims NA; Vieusseux J; Waldeck K; Docherty SE; Myers D; Nakamura A; Waltham MC; Gillespie MT; Thompson EW
Cancer Res; 2005 Jun; 65(11):4929-38. PubMed ID: 15930315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]